Key result
Gradient boosting risk models trained on Mexican data achieve 0.83 AUC for predicting undiagnosed diabetes.
Why the study?
Diabetes and hypertension carry severe health and socioeconomic impacts, and tools are needed for early detection of these conditions, visual complications, and COVID-19 risk stratification.
Do state-of-the-art risk models improve the accuracy and equity of predicting diabetes, hypertension, visual complications, and severe COVID-19 in the Mexican population compared to established benchmarks?
Observational (n=43,071)
Do state-of-the-art risk models improve the accuracy and equity of predicting diabetes, hypertension, visual complications, and severe COVID-19 in the Mexican population compared to established benchmarks?
Answers are grounded in this paper and cite their sources.
Machine learning-based risk models using publicly available data can accurately and equitably predict the risk of diabetes, hypertension, visual complications, and severe COVID-19 in the Mexican population.
BACKGROUND Diabetes and hypertension are among top public health priorities, particularly in low and middle-income countries where their health and socioeconomic impact is exacerbated by the quality and accessibility of health care. Moreover, their connection with severe or deadly COVID-19 illness has further increased their societal relevance. Tools for early detection of these chronic diseases enable interventions to prevent high-impact complications, such as loss of sight and kidney failure. Similarly, prognostic tools for COVID-19 help stratify the population to prioritize protection and vaccination of high-risk groups, optimize medical resources and tests, and raise public awareness. METHODS We developed and validated state-of-the-art risk models for the presence of undiagnosed diabetes, hypertension, visual complications associated with diabetes and hypertension, and the risk of severe COVID-19 illness (if infected). The models were estimated using modern methods from the field of statistical learning (e.g., gradient boosting trees), and were trained on publicly available data containing health and socioeconomic information representative of the Mexican population. Lastly, we assembled a short integrated questionnaire and deployed a free online tool for massifying access to risk assessment. RESULTS Our results show substantial improvements in accuracy and algorithmic equity (balance of accuracy across population subgroups), compared to established benchmarks. In particular, the models: i) reached state-of-the-art sensitivity and specificity rates of 90% and 56% (0.83 AUC) for diabetes, 80% and 64% (0.79 AUC) for hypertension, 90% and 56% (0.84 AUC) for visual diminution as a complication, and 90% and 60% (0.84 AUC) for development of severe COVID disease; and ii) achieved substantially higher equity in sensitivity across gender, indigenous/non-indigenous, and regional populations. In addition, the most relevant features used by the models were in line with risk factors commonly identified by previous studies. Finally, the online platform was deployed and made accessible to the public on a massive scale. CONCLUSIONS The use of large databases representative of the Mexican population, coupled with modern statistical learning methods, allowed the development of risk models with state-of-the-art accuracy and equity for two of the most relevant chronic diseases, their eye complications, and COVID-19 severity. These tools can have a meaningful impact on democratizing early detection, enabling large-scale preventive strategies in low-resource health systems, increasing public awareness, and ultimately raising social well-being.
No takes yet. Share an insight, caveat, or question.
Amaya et al. (2021) conducted an observational in Diabetes, hypertension, visual diminution, and COVID-19 (n=43,071). Gradient boosting risk models vs. Established benchmark risk calculators (e.g., ADA, LA-FINDRISC, IMSS) was evaluated on Area under the receiver operating characteristic curve (AUC) for undiagnosed diabetes. Gradient boosting risk models trained on Mexican population data achieved state-of-the-art accuracy, reaching an AUC of 0.83 for diabetes, 0.79 for hypertension, 0.84 for visual diminution, and 0.84 for COVID-19 severity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: